Nivolumab for previously treated unresectable advanced oesophageal cancer [ID1249]: appraisal consultation
We are listening to your views on this technology appraisal guidance. Comments close 25 November 2020.
Search results
4 results
-
-
Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease (CDF Review of TA558) [ID1681]: appraisal consultation
We are listening to your views on this technology appraisal guidance. Comments close 25 November 2020.
-
Midostaurin for treating advanced systemic mastocytosis ID1573: appraisal consultation
We are listening to your views on this technology appraisal guidance. Comments close 27 November 2020.
-
Fostamatinib for treating persistent or chronic immune thrombocytopenia [ID1087]: appraisal consultation
We are listening to your views on this technology appraisal guidance. Comments close 02 December 2020.